View in EDS HTML Full Text PDF Full Text

Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanoma.

Saved in:
Bibliographic Details
Title: Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanoma.
Authors: Mao Y; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia., Gide TN; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia., Maher NG; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.; Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia., Vignati D; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia., Boutros A; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Department of Internal Medicine and Medical Specialties (DiMI), University of Genoa, Genova, Italy., Cornejo-Páramo P; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia., Potter AJ; Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia., Carlino MS; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Westmead and Blacktown Hospitals, Sydney, NSW, Australia., Paver EC; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; The Canberra Hospital, Canberra, ACT, Australia.; College of Science and Medicine, Australian National University, Canberra, ACT, Australia., Burke H; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia., Menzies AM; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Mater Hospital, North Sydney, Sydney, NSW, Australia.; Royal North Shore Hospital, Sydney, NSW, Australia., Lo SN; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia., da Silva IP; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.; Champalimaud Foundation, Lisbon, Portugal., Scolyer RA; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.; Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia., Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.; Mater Hospital, North Sydney, Sydney, NSW, Australia.; Royal North Shore Hospital, Sydney, NSW, Australia., Vergara IA; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia., Wilmott JS; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia. james.wilmott@sydney.edu.au.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia. james.wilmott@sydney.edu.au.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia. james.wilmott@sydney.edu.au.
Source: NPJ precision oncology [NPJ Precis Oncol] 2026 Jan 22; Vol. 10 (1), pp. 55. Date of Electronic Publication: 2026 Jan 22.
Publication Type: Journal Article
Journal Info: Publisher: Springer Nature Country of Publication: England NLM ID: 101708166 Publication Model: Electronic Cited Medium: Print ISSN: 2397-768X (Print) Linking ISSN: 2397768X NLM ISO Abbreviation: NPJ Precis Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41571736
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Mao+Y%22">Mao Y</searchLink>; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22Gide+TN%22">Gide TN</searchLink>; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22Maher+NG%22">Maher NG</searchLink>; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.; Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22Vignati+D%22">Vignati D</searchLink>; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22Boutros+A%22">Boutros A</searchLink>; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Department of Internal Medicine and Medical Specialties (DiMI), University of Genoa, Genova, Italy.<br /><searchLink fieldCode="AU" term="%22Cornejo-Páramo+P%22">Cornejo-Páramo P</searchLink>; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22Potter+AJ%22">Potter AJ</searchLink>; Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22Carlino+MS%22">Carlino MS</searchLink>; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Westmead and Blacktown Hospitals, Sydney, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22Paver+EC%22">Paver EC</searchLink>; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; The Canberra Hospital, Canberra, ACT, Australia.; College of Science and Medicine, Australian National University, Canberra, ACT, Australia.<br /><searchLink fieldCode="AU" term="%22Burke+H%22">Burke H</searchLink>; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22Menzies+AM%22">Menzies AM</searchLink>; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Mater Hospital, North Sydney, Sydney, NSW, Australia.; Royal North Shore Hospital, Sydney, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22Lo+SN%22">Lo SN</searchLink>; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22da+Silva+IP%22">da Silva IP</searchLink>; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.; Champalimaud Foundation, Lisbon, Portugal.<br /><searchLink fieldCode="AU" term="%22Scolyer+RA%22">Scolyer RA</searchLink>; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.; Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22Long+GV%22">Long GV</searchLink>; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.; Mater Hospital, North Sydney, Sydney, NSW, Australia.; Royal North Shore Hospital, Sydney, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22Vergara+IA%22">Vergara IA</searchLink>; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22Wilmott+JS%22">Wilmott JS</searchLink>; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia. james.wilmott@sydney.edu.au.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia. james.wilmott@sydney.edu.au.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia. james.wilmott@sydney.edu.au.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101708166%22">NPJ precision oncology</searchLink> [NPJ Precis Oncol] 2026 Jan 22; Vol. 10 (1), pp. 55. <i>Date of Electronic Publication: </i>2026 Jan 22.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Nature%22">Springer Nature </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101708166 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Print <i>ISSN: </i>2397-768X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222397768X%22">2397768X </searchLink><i>NLM ISO Abbreviation: </i>NPJ Precis Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41571736
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41698-025-01230-y
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 55
    Titles:
      – TitleFull: Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Mao Y
      – PersonEntity:
          Name:
            NameFull: Gide TN
      – PersonEntity:
          Name:
            NameFull: Maher NG
      – PersonEntity:
          Name:
            NameFull: Vignati D
      – PersonEntity:
          Name:
            NameFull: Boutros A
      – PersonEntity:
          Name:
            NameFull: Cornejo-Páramo P
      – PersonEntity:
          Name:
            NameFull: Potter AJ
      – PersonEntity:
          Name:
            NameFull: Carlino MS
      – PersonEntity:
          Name:
            NameFull: Paver EC
      – PersonEntity:
          Name:
            NameFull: Burke H
      – PersonEntity:
          Name:
            NameFull: Menzies AM
      – PersonEntity:
          Name:
            NameFull: Lo SN
      – PersonEntity:
          Name:
            NameFull: da Silva IP
      – PersonEntity:
          Name:
            NameFull: Scolyer RA
      – PersonEntity:
          Name:
            NameFull: Long GV
      – PersonEntity:
          Name:
            NameFull: Vergara IA
      – PersonEntity:
          Name:
            NameFull: Wilmott JS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 22
              M: 01
              Text: 2026 Jan 22
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 2397-768X
          Numbering:
            – Type: volume
              Value: 10
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: NPJ precision oncology
              Type: main
ResultId 1